Intrathecal Baclofen for Spasticity Management: A Comparative Analysis of Spasticity of Spinal vs Cortical Origin

REFERENCES

• Vender JR, Hughes M, Hughes BD, Hester S, Holsenback S, Rosson B. Intrathecal baclofen therapy and multiple sclerosis: outcomes and patient satisfaction. Neurosurg Focus. 2006; 21(2): e6.
   PubMedGoogle Scholar
• Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil. 1999; 80(4): 13–19.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am J Phys Med Rehabil. 1999; 78(3): 247–254.
   PubMed Web of Science ®Google Scholar
• Ridley B. Intrathecal baclofen therapy: challenges in patients with multiple sclerosis. Rehabil Nurs. 2006; 31(4): 158–164.
   PubMed Web of Science ®Google Scholar
• Smail BD, Peskine A, Roche N, Mailhan L, Thiebaut JB, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler. 2006; 12(1): 101–103.
   PubMed Web of Science ®Google Scholar
• Hsieh JC, Penn RD. Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus. 2006; 21 (2): e5.
   PubMedGoogle Scholar
• Coffey RJ, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993; 78(2): 226–232.
   PubMed Web of Science ®Google Scholar
• Rawlins PK. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs. 2004; 36(6): 322–327.
   PubMedGoogle Scholar
• Katz RT. Management of spasticity. Am J Phys Med. 1988; 67(3): 108–116.
   Google Scholar
• Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatr. 1994; 57(7): 773–777.
   PubMed Web of Science ®Google Scholar
• Wahlquist GI. Evaluation and primary management of spasticity. Nurse Pract. 1987; 12(3): 27–32.
   PubMedGoogle Scholar
• Knutsson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci. 1974; 23(3): 473–484.
   PubMed Web of Science ®Google Scholar
• Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989; 320(23): 1517–1521.
   PubMed Web of Science ®Google Scholar
• Ordia Jl, Fischer E, Adamski E, Chagnon KG, Spatz EL. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation. 2002; 5(1): 16–24.
   PubMed Web of Science ®Google Scholar
• Schiess M, Furr ES, Fisher S, Acosta F, Richard S, Izor R. Functional motor improvement in stroke related spastic hemiparesis after intrathecal baclofen pump therapy. Neurology. 2006; 66: A324–A.
   PubMedGoogle Scholar
• Francisco GE, Yablon SA, Schiess MC, Wiggs L, Cavalier S, Grissom S. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil. 2006; 13(14): 74–85.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN, Francisco GE. Intrathecal baclofen for spastic hypertonia from stroke. Commentary. Stroke. 2001; 32(9): 2099–2109.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadley MN. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil. 2001; 82(2): 155–161.
   PubMed Web of Science ®Google Scholar
• Korenkov Al, Niendorf WR, Darwish N, Glaeser E, Gaab MR. Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurg Rev. 2002; 25(4): 228–230.
   PubMed Web of Science ®Google Scholar
• Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long- erm follow-up. Arch Phys Med Rehabil. 1996; 77(1): 35–39.
   PubMed Web of Science ®Google Scholar
• Francisco GE. Intrathecal baclofen therapy for stroke-related spasticity. Top Stroke Rehabil. 2001; 8(1): 36–46.
   PubMedGoogle Scholar
• Francisco GE, Hu MM, Boake C, Ivanhoe CB. Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj. 2005; 19(5): 359–364.
   PubMed Web of Science ®Google Scholar
• Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Gussom SP. Intrathecal baclofen management of post-stroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006; 87(11): 1509–1515.
   PubMed Web of Science ®Google Scholar
• Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughlin JF. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg. 2003; 98(2): 291–295.
   PubMed Web of Science ®Google Scholar
• Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin, J Neurol Neurosurg Psychiatr. 2004; 75(11): 1553–1557.
   PubMed Web of Science ®Google Scholar
• Nielsen JF, Hansen HJ, Sunde N, Christensen JJ. Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg. 2002; 104(2): 142–145.
   PubMed Web of Science ®Google Scholar
• Akman MN, Loubser PG, Donovan WH, O'Neill ME, Rossi CD. Intrathecal baclofen: does tolerance occur? Paraplegia. 1993; 31(8): 516–520.
   Google Scholar
• Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005; 107(4): 289–295.
   PubMed Web of Science ®Google Scholar